An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time

Expert Opinion on Biological Therapy

Volumn 12, Issue 12, 2012, Pages 1601-1610

  Romano, Marta ^a   Huygen, Kris ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Clinical trials; Cytolytic t cells; Dna vaccine; Latency; Prime boost protocols; Tuberculosis; Vaccine

Indexed keywords

ADAG 85A; AERAS 402; AERAS 422; BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; GSK 692342; HYBRID 1; ID 93; IKEPLUS; INTERLEUKIN 17; INTERLEUKIN 2; LIVE VACCINE; MVA AG 85A; RUTI VACCINE; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VPM 1002;

ADAPTIVE IMMUNITY; BACTERIAL IMMUNITY; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SCREENING; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TH1 CELL; TUBERCULOSIS;

ANIMALS; BCG VACCINE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84869429756     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.721768     Document Type: Review

References (62)

1. Wirth T, Hildebrand F, Allix- Buegec C. Origin, spread and demography of the mycobacterium tuberculosis complex. PLoS Pathog 2008;4:e1000160
2. WHO 2011. Global tuberculosis control 2011. Available from: who int/tb/publications/global report 2011
3. North RJ, Jung YJ. Immunity to Tuberculosis. Annu Rev Immunol 2004;22:599-623
4. Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: A web-based algorithm to aid the interpretation of tuberculin skin test results. Intl J Tuberc Lung Dis 2008;12:498-505
5. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21
6. WHO Guidelines 2011. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Available from: Who int/hiv/pub/tb/9789241500708 2011
7. Jackson M, Yamamoto S. Historical background of Mycobacterium bovis BCG. In: TAKII T, Maeyama J, Yamamoto S, editors. BCG -vaccine and adjuvant. Japan Anti-Tuberculosis Association; Tokyo: 2011. p. 3-12
8. Kaufmann S, Gengerbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012;Epub ahead of print 9. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. JAMA 1994;271:689-702
9. Fine PEM. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995;346:1339-45
10. Colditz G, Berkey C, Mosteller F. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature. Pediatrics 1995;96:29-35
11. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann Rev Pathol 2012;7:353-84
12. Corbett EL. HIV and tuberculosis: Surveillance revisited. Intl J Tuberc Lung Dis 2003;7:709
13. Casanova JL, Abel L. The human model: A genetic dissection of immunity to infection in natural conditions. Nature Rev Immunol 2004;4:55-66
14. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161:1-9
15. Caccamo N, Guggino G, Meraviglia S, et al. Analysis of mycobacterium tuberculosis -specific CD8+ T cells in patients with active tuberculosis and in individuals with latent infection. PLoS One 2009;4:e5528
16. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77
17. Kagina BM, Abel B, Scriba TJ, Hughes E. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-9
18. Ottenhoff TH, Ellner JJ, Kaufmann SH. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012;92:S17-20
19. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophildriven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-7
20. Maertzdorf J, Ota M, Repsilber D, et al. Functional correlations of pathogenesisdriven gene expression signatures in tuberculosis. PLoS One 2011;6:e26938
21. Kunnath-Velayudhan S, Gennaro ML. Immunodiagnosis of tuberculosis: A dynamic view of biomarker discovery. Clin Microbiol Rev 2011;24:792-805
22. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis: Insights into pathogenesis and protection. Am J Respir Crit Care Med 2011;183:696-707
23. BrennanMJ, Thole J. Tuberculosis vaccines: A strategic blueprint for the next decade. Tuberculosis (Edinb) 2012;92:S6-S13
24. Stop TB Partnership Working Group on New TB Vaccines. Tuberculosis Vaccine Pipeline-2011. StopTB partnership 2011
25. Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: Where are we and where do we need to go ? PLoS Pathog 2012;8:e1002607
26. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, et al. PhoP: A missing piece in the intricate puzzle of mycobacterium tuberculosis Virulence. PLoS one 2008;3:e3496
27. Sterne JAC, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200-7
28. Mori T. Efficacy of BCG vaccination. In: TAKII T, Maeyama J-I, Yamamoto S, editors. BCG- vaccine and aduvant. Japan Anti-Tuberculosis Association; Tokyo: 2011. p. 13-45
29. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60 year follow-up study. JAMA 2004;291:2086-91
30. Dye C. A booster for tuberculosis vaccines. JAMA 2004;291:2127-8
31. Andersen P, Doherty M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656-65
32. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3
33. Checkley AM, McShane H. Tuberculosis vaccines: Progress and chalenges. Trends Pharm Sci 2011;32:601-6
34. Minassian AM, Satti I, Poulton ID, et al. A human challenge model for mycobacterium tuberculosis using mycobacterium bovis bacille calmette-guerin. J Infect Dis 2012;205:1035-42
35. Kampmann B, Tena GN, Mzazi S, et al. Novel human in vitro system for evaluating antimycobacterial vaccines. Infect Immun 2004;72:6401-7
36. Higbee RG, Byers AM, Dhir V. An immunologic model for rapid vaccine assessment - a clinical trial in a test tube. Altern Lab Anim 2009;37:19-27
37. Sweeney KA, Dao DN, Goldberg MF, et al. A recombinant mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011;17:1261-8
38. Barkan D, Hedhli D, Yan H-G, et al. Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. Infect Immun 2012;80:1958-68
39. Dao DN, Sweeney K, Hsu T, et al. Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog 2008;4:e1000081
40. Vander Beken S, Dulayymi J, Naessens et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur J Immunol 2011;41:450-60
41. Warrier T, Tropis M, Werngren J, et al. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob Agents Chemother 2012;56:1735-43
42. Festjens N, Bogaert P, Batni A, et al. Disruption of the SapM locus in mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO Mol Med 2011;3:222-34
43. Copenhaver RH, Sepulveda E, Armitige LY, et al. A Mutant of mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 2004;72:7084-95
44. Saikolappan S, Estrella J, Sasindran SJ, et al. The fbpA/SapM double knock out strain of mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages. PLoS One 2012;7:e36198
45. BrennanMJ, Clagett B, FitzgeraldH, et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012;30:2811-23
46. Kutzler MA, Weiner DB. DNA vaccines: Ready for prime time? Nat Rev Genet 2008;9:776-88
47. Ryan AA, Nambiar JK, Wozniak TM, et al. Antigen load governs the differential priming of CD8+ T cells in response to BCG vaccine or M. tuberculosis. J Immunol 2009;182:7172-7
48. Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009;8:1237-50
49. Romano M,D'Souza S, Adnet PY, et al. Priming but not boosting with plasmid DNA encodingmycolyl-transferase Ag85A fromM. tuberculosis increases the survival time of M. bovis BCGvaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006;24:3353-64
50. Dou J, Wang Y, Yu F, et al. Protection against mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:183-90
51. Lin MY, Geluk A, Verduyn M, et al. BCG vaccination induces poor responses against DosR regulon encoded antigens that are upregulated in latent Mycobacterium tuberculosis infection. Infect Immun 2007;75:3523-30
52. Roupie V, Romano M, Zhang L, et al. Immunogenicity of eight dormancy (DosR) regulon encoded proteins of mycobacterium tuberculosis in DNA vaccinated and tuberculosisinfected mice. Infect Immun 2007;75:941-9
53. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422
54. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb) 2007;87:257-66
55. Hokey DA, Misra A. Aerosol vaccines for tuberculosis: A fine line between protection and pathology. Tuberculosis (Edinb) 2011;91:82-5
56. Jeyanathan M, Mu J, Kugathasan K, et al. Airway Delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: Role of proinflammatory signals in the lungs. J Immunol 2008;181:5618-26
57. Gupta A, Gheeta N, Mani J, et al. Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route 51. 2009;77:223-31
58. Rodriguez A, Tjarnlund A, Ivanyi J, et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 2005;23:2565-72
59. Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011;186:3113-19
60. Tchillian EZ, Ronan EO, de Lara C, et al. Simultaneous immunization against tuberculosis. PLoS One 2011;6:e27477
61. Schandevyl M. Geschiedenis van de tuberculose. Berichten VRGT (Vlaamse Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding) 2012;21:4-7
62. McShane H, Pathan AA, Sander C, et al. Recombinant modified vaccinia ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med 2004;10:1240-4